As Biotechnology companies, INSYS Therapeutics Inc. (NASDAQ:INSY) and uniQure N.V. (NASDAQ:QURE) are our subject to contrast. And more specifically their risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership.
Valuation and Earnings
Demonstrates INSYS Therapeutics Inc. and uniQure N.V. earnings per share (EPS), top-line revenue and valuation.
Table 2 shows us the return on equity, return on assets and net margins of both companies.
A 2.56 beta indicates that INSYS Therapeutics Inc. is 156.00% more volatile compared to SP 500. From a competition point of view, uniQure N.V. has a 1.07 beta which is 7.00% more volatile compared to SP 500.
The current Quick Ratio of INSYS Therapeutics Inc. is 0.6 while its Current Ratio is 0.7. Meanwhile, uniQure N.V. has a Current Ratio of 7.6 while its Quick Ratio is 7.6. uniQure N.V. is better positioned to pay off its